GlassScriptPhysician profile
Abigail L Lore
NPI 1124325063
$4,941.05
in general payments reported to CMS, 2019-2025
38 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $204 · 2021: $825 · 2022: $523 · 2023: $793 · 2024: $901 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,010.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $481.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $458.56 | 2021-2025 | |
| Lilly USA, LLC | $424.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.61 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $247.95 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $219.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $184.94 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Amgen INC. | $180.16 | 2022-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $122.31 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $113.44 | 2019-2021 | |
| Daiichi Sankyo INC. | $108.16 | 2019-2024 | Injectafer |
| Exact Sciences Corporation | $91.81 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $88.79 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $88.59 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Lore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.